{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:34:46Z","timestamp":1781732086457,"version":"3.54.5"},"reference-count":29,"publisher":"Norwegian Medical Association","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.18.0383","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T08:23:28Z","timestamp":1542097408000},"source":"Crossref","is-referenced-by-count":7,"title":["Bruk av medikamenter for alkoholbrukslidelser i Norge 2004\u201316"],"prefix":"10.4045","volume":"138","author":[{"given":"Anne Taraldsen","family":"Heldal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Paul Koren","family":"Lobmaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-K\u00e5re","family":"Vederhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen G.","family":"Bramness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Rehm\u00a0J, Room\u00a0R, Graham\u00a0K et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 2003; 98: 1209\u201328. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12930209&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1046%2Fj.1360-0443.2003.00467.x","DOI":"10.1046\/j.1360-0443.2003.00467.x"},{"key":"ref=2","unstructured":"Gjelsvik R. Utredning av de samfunnsmessige kostnadene relatert til alkohol. Notatserie i helse\u00f8konomi. Nr. 07\/04. Bergen: Rokkansenteret, 2004."},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Kringlen\u00a0E, Torgersen\u00a0S, Cramer\u00a0V. A Norwegian psychiatric epidemiological study. Am J Psychiatry 2001; 158: 1091\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11431231&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1176%2Fappi.ajp.158.7.1091","DOI":"10.1176\/appi.ajp.158.7.1091"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Kringlen\u00a0E, Torgersen\u00a0S, Cramer\u00a0V. Mental illness in a rural area: a Norwegian psychiatric epidemiological study. Soc Psychiatry Psychiatr Epidemiol 2006; 41: 713\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16732397&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00127-006-0080-0","DOI":"10.1007\/s00127-006-0080-0"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Torvik\u00a0FA, Ystrom\u00a0E, Gustavson\u00a0K et al. Diagnostic and genetic overlap of three common mental disorders in structured interviews and health registries. Acta Psychiatr Scand 2018; 137: 54\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29072781&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Facps.12829","DOI":"10.1111\/acps.12829"},{"key":"ref=6","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders : diagnostic criteria for research. Geneva: World Health Organization, 1993. http:\/\/www.who.int\/classifications\/icd\/en\/GRNBOOK.pdf (24.9.2018)."},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Thompson\u00a0A, Ashcroft\u00a0DM, Owens\u00a0L et al. Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS One 2017; 12: e0173272. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28319159&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pone.0173272","DOI":"10.1371\/journal.pone.0173272"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Mark\u00a0TL, Kassed\u00a0CA, Vandivort-Warren\u00a0R et al. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 2009; 99: 345\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18819759&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.drugalcdep.2008.07.018","DOI":"10.1016\/j.drugalcdep.2008.07.018"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Shield\u00a0KD, Rehm\u00a0J, Gmel\u00a0G et al. Alcohol consumption, alcohol dependence, and related mortality in Italy in 2004: effects of treatment-based interventions on alcohol dependence. Subst Abuse Treat Prev Policy 2013; 8: 21. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23758914&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2F1747-597X-8-21","DOI":"10.1186\/1747-597X-8-21"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Rehm\u00a0J, Barbosa\u00a0C. The cost-effectiveness of therapies to treat alcohol use disorders. Expert Rev Pharmacoecon Outcomes Res 2018; 18: 43\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29022750&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F14737167.2018.1392241","DOI":"10.1080\/14737167.2018.1392241"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Rehm\u00a0J, Shield\u00a0KD, Gmel\u00a0G et al. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 2013; 23: 89\u201397. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22920734&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.euroneuro.2012.08.001","DOI":"10.1016\/j.euroneuro.2012.08.001"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Haass-Koffler\u00a0CL, Akhlaghi\u00a0F, Swift\u00a0RM et al. Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks? J Psychopharmacol 2017; 31: 812\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28093021&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881116684338","DOI":"10.1177\/0269881116684338"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Skinner\u00a0MD, Lahmek\u00a0P, Pham\u00a0H et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 2014; 9: e87366. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24520330&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pone.0087366","DOI":"10.1371\/journal.pone.0087366"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Goh\u00a0ET, Morgan\u00a0MY. Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Aliment Pharmacol Ther 2017; 45: 865\u201382. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28220511&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fapt.13965","DOI":"10.1111\/apt.13965"},{"key":"ref=15","unstructured":"M\u00f8rland\u00a0J. Legemidler mot alkoholmisbruk. Tidsskr Nor L\u00e6geforen 2006; 126: 3268\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17170774&dopt=Abstract"},{"key":"ref=16","unstructured":"Bachs\u00a0L, Waal\u00a0H. Behandling av opioidavhengige med naltrekson. Tidsskr Nor L\u00e6geforen 2003; 123: 1665\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12821984&dopt=Abstract"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"R\u00f6sner\u00a0S, Hackl-Herrwerth\u00a0A, Leucht\u00a0S et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;  12: CD001867. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21154349&dopt=Abstract","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Gual\u00a0A, He\u00a0Y, Torup\u00a0L et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23: 1432\u201342. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23562264&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.euroneuro.2013.02.006","DOI":"10.1016\/j.euroneuro.2013.02.006"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"van den Brink\u00a0W, S\u00f8rensen\u00a0P, Torup\u00a0L et al. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J Psychopharmacol 2014; 28: 733\u201344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24671340&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881114527362","DOI":"10.1177\/0269881114527362"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Palpacuer\u00a0C, Duprez\u00a0R, Huneau\u00a0A et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 2018; 113: 220\u201337. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28940866&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fadd.13974","DOI":"10.1111\/add.13974"},{"key":"ref=21","unstructured":"Slagsvold B, L\u00f8set GK. Eldres alkoholkonsum. Utviklingstrekk og \u00e5rsaker. Hva forteller NorLAG-studien? NOVA rapport 15\/13. Oslo: NOVA, 2014. http:\/\/www.forebygging.no\/Global\/artikkel%20Eldre%20og%20alkohol,%20endelig.pdf (24.9.2018)."},{"key":"ref=22","unstructured":"Folkehelserapporten \u2013 kortversjonen. Helsetilstanden i Norge 2018. Folkehelseinstituttet, 2018: 32 https:\/\/www.fhi.no\/globalassets\/dokumenterfiler\/rapporter\/2018\/helsetilstanden-i-norge-20182.pdf (24.9.2018)."},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Lid\u00a0TG, Nesv\u00e5g\u00a0S, Meland\u00a0E. When general practitioners talk about alcohol: exploring facilitating and hampering factors for pragmatic case finding. Scand J Public Health 2015; 43: 153\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25564115&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F1403494814565129","DOI":"10.1177\/1403494814565129"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Soyka\u00a0M, R\u00f6sner\u00a0S. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. Curr Drug Abuse Rev 2008; 1: 280\u201391. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19630726&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2174%2F1874473710801030280","DOI":"10.2174\/1874473710801030280"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Roos\u00a0CR, Mann\u00a0K, Witkiewitz\u00a0K. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addict Biol 2017; 22: 1528\u201339. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27480445&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fadb.12427","DOI":"10.1111\/adb.12427"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Kalk\u00a0NJ, Lingford-Hughes\u00a0AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol 2014; 77: 315\u201323. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23278595&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fbcp.12070","DOI":"10.1111\/bcp.12070"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Campbell\u00a0EJ, Lawrence\u00a0AJ, Perry\u00a0CJ. New steps for treating alcohol use disorder. Psychopharmacology (Berl) 2018; 235: 1759\u201373. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29574507&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00213-018-4887-7","DOI":"10.1007\/s00213-018-4887-7"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Soyka\u00a0M, Kranzler\u00a0HR, Hesselbrock\u00a0V et al. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World J Biol Psychiatry 2017; 18: 86\u2013119. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28006997&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F15622975.2016.1246752","DOI":"10.1080\/15622975.2016.1246752"},{"key":"ref=29","unstructured":"Nasjonal faglig retningslinje for avrusning fra rusmidler og vanedannende legemidler. IS-2211. Oslo: Helsedirektoratet, 2016. https:\/\/helsedirektoratet.no\/Retningslinjer\/Avrusning%20fra%20rusmidler%20og%20vanedannende%20legemidler.pdf (24.9.2018)."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:03:15Z","timestamp":1781679795000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2018\/11\/originalartikkel\/bruk-av-medikamenter-alkoholbrukslidelser-i-norge-2004-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":29,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.18.0383","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]}}}